DFW Capital Partners portfolio company, Vidara Therapeutics, completes its previously-announced sale

DFW Capital Partners announced today that it has completed the sale of its portfolio company, Vidara Therapeutics Ltd to Horizon Pharma in a cash and stock transaction valued at approximately $587 million. 

Vidara is a leading specialty pharmaceutical developer and marketer, focused on rare disease and niche therapies in the orphan drug arena.  DFW originally invested in Vidara in 2012, supporting its acquisition of Actimmune®, a patented biologic injectable form of interferon gamma-1b, approved for the treatment of Chronic Granulomatous Disease (CGD) and severe, malignant osteopetrosis.  DFW partnered with two of its operating affiliates, Virinder Nohria and Bala Venkataraman, to fund the acquisition and lead a team which successfully repositioned the Actimmune® product in the marketplace, created vastly improved patient access, physician support and disease state awareness, and has initiated numerous longer-term growth initiatives for the product.  Vidara’s growth during this period led to the transaction with Horizon, where the Actimmune® product and team will become an integral part of the Horizon portfolio and growth strategy.

Keith Pennell, DFW’s Managing Partner, commented “we are thrilled with the outstanding operational and financial success that Vidara’s team has accomplished in a relatively short period, and are equally excited to achieve both a successful financial exit and go-forward affiliation with Horizon and its talented management team.”

DFW invested in Vidara through its third dedicated private equity fund, DFW Capital Partners III, L.P.  Lazard Middle Market represented Vidara and its shareholders in the transaction.

Horizon’s press release link: http://ir.horizon-pharma.com


About DFW Capital Partners

DFW Capital Partners is a private equity investment firm focused on lower middle-market companies.  The firm concentrates on service companies, with an emphasis on healthcare and outsourced business and industrial support services.  DFW is backed by both institutional and high-net worth individual investors, and has established a 20+ year track record of success in both building leading companies, and recognizing outstanding returns for its investors. DFW is headquartered in Teaneck, NJ, and maintains an office in Chevy Chase, MD. For more information contact Keith Pennell, Managing Partner, at (201) 836-6000(201) 836-6000.